653. Multiple Myeloma: Clinical and Epidemiological: Poster II
0 activities
Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation in a UK General Popula...
1 activities
Absolute Risk of Multiple Myeloma Is Quite Modest in Individuals with Incidentally Discovered Vertebral Fractures: A Prospective Cohort Study of 9,065 CT-Scanned Danish General Population Individuals with Independent Validation
An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
1 activities
An International Study of 343 Newly Diagnosed MM Patients with Acute Renal Failure Due to Cast Nephropathy: Assessment of Factors Affecting Renal Response
Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
1 activities
Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma
Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry
1 activities
Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry
Characterizing Genomic Variants Defining a Plasma Cell Disorder Patient Cohort Using a Broad Next Generation Multi-Gene DNA Sequencing Panel
1 activities
Characterizing Genomic Variants Defining a Plasma Cell Disorder Patient Cohort Using a Broad Next Generation Multi-Gene DNA Sequencing Panel
Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
1 activities
Clinical, Biological and Prognostic Characterization of Multiple Myeloma According to the Presence of Circulating Plasma Cells
Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA
1 activities
Comprehensive (Epi)Genetic Tumor Characterization and Disease Follow-Up in Multiple Myeloma Using Blood-Derived Cell-Free DNA
Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
1 activities
Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis
Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
1 activities
Delayed Neutrophil Recovery Following BCMA-Directed CAR-T Correlates with Poor Outcomes and Is Associated with a Cytokine Signature of Persistent Inflammation and T Cell Checkpoint Activation
Differential Diagnosis of Multiple Myeloma and Systemic Light Chain Amyloidosis Using Plasma Cell Morphology Based on Deep Learning
1 activities
Differential Diagnosis of Multiple Myeloma and Systemic Light Chain Amyloidosis Using Plasma Cell Morphology Based on Deep Learning
Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma
1 activities
Dynamics of Geriatric Impairments Are Associated with Risk of Treatment Discontinuation in Elderly Patients with Multiple Myeloma
Early Responders (Time to Best Response ≤3 months) Predicts Functional High-Risk Multiple Myeloma
1 activities
Early Responders (Time to Best Response ≤3 months) Predicts Functional High-Risk Multiple Myeloma
Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
1 activities
Evaluation of the Safety and Efficacy of Denosumab in Patients with Multiple Myeloma and Severe Renal Impairment; Results from an IMWG Bone Subcommittee Study
Genome Scale Prediction of Functional Target Networks Uncovers Candidate Vulnerabilities in Sky-92 High Risk Multiple Myeloma
1 activities
Genome Scale Prediction of Functional Target Networks Uncovers Candidate Vulnerabilities in Sky-92 High Risk Multiple Myeloma
Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study
1 activities
Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone
Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality
1 activities
Hypogammaglobulinemia and Daratumumab in Multiple Myeloma: Risk Factors, Infections, Immunoglobulin Replacement, and Mortality
Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach
1 activities
Identifying 5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA and Treatment Response in Multiple Myeloma with a Multi-Step Machine Learning Approach
Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
1 activities
Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group
1 activities
Impact of Pre-Transplant Depth of Response on Outcomes in Patients with Multiple Myeloma: A Report on Behalf of Pakistan Blood and Marrow Transplant Group
Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis
1 activities
Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis
NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
1 activities
NGS-Based Immunoglobulin Gene Sequencing for Diagnosis and MRD Monitoring of Multiple Myeloma
Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
1 activities
Optimal Treatment for Newly Diagnosed Primary Plasma Cell Leukemia: A Retrospective Multicenter Analysis
Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
1 activities
Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant
Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care
1 activities
Outcomes of Relapsed and Refractory Multiple Myeloma with the Evolving Standard of Care
Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies
1 activities
Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies
Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
1 activities
Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab
Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients
1 activities
Prevalence and Clinical Implications of Germline Variants in Multiple Myeloma Patients
Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades
1 activities
Real-World Treatment Sequencing, Attrition Rates, and Survival Outcomes in Multiple Myeloma: A Retrospective Study over Four Decades
Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
1 activities
Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial
Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
1 activities
Risk Factors for Suboptimal Treatment in Patients with Newly Diagnosed Multiple Myeloma across US Healthcare Systems
Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
1 activities
Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
1 activities
Soluble BCMA As a Surrogate Biomarker for Tumor Burden in Multiple Myeloma: Correlations with Various Biomarkers and Treatment Responses
Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
1 activities
Soluble BCMA Dynamics in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1
Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
1 activities
Stratifying 'frail' Patients Defined By the Simplified Frailty Scale in Multiple Myeloma: Correlation with Clinical Outcomes
Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)
1 activities
Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)